Clinical Trials
125 trialsNCT04704934 2026-05-27
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
Daiichi Sankyo
Phase 3 Active not recruiting
NCT06311214 2026-05-27
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT07137416 2026-05-27
Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT07578116 2026-05-27
Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis
SWOG Cancer Research Network
Phase 3 Not yet recruiting
NCT06324357 2026-05-26
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Boehringer Ingelheim
Phase 1/2 Recruiting
NCT06819007 2026-05-26
DO-01
Daiichi Sankyo
Phase 3 Recruiting
NCT04784715 2026-05-22
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
AstraZeneca
Phase 3 Active not recruiting
NCT07060807 2026-05-22
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT04585958 2026-05-20
Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT05372614 2026-05-18
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
National Cancer Institute (NCI)
Phase 1 Suspended
NCT07069712 2026-05-18
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
AstraZeneca
Phase 2 Recruiting
NCT04622319 2026-05-15
DESTINY-Breast05
Daiichi Sankyo
Phase 3 Active not recruiting
NCT06467357 2026-05-14
DESTINY-BTC01
AstraZeneca
Phase 3 Recruiting
NCT04379596 2026-05-13
DG-03
AstraZeneca
Phase 2 Recruiting
NCT04616560 2026-05-13
Trastuzumab Deruxtecan for the Treatment of HER2+ Newly Diagnosed or Recurrent Osteosarcoma
National Cancer Institute (NCI)
Phase 2 Suspended
NCT04704661 2026-05-13
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT06364410 2026-05-13
Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT07012031 2026-05-13
Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation
National Cancer Institute (NCI)
Phase 1/2 Recruiting
NCT04739761 2026-05-12
DESTINY-B12
AstraZeneca
Phase 3 Active not recruiting
NCT05246514 2026-05-12
DL-05
AstraZeneca
Phase 2 Active not recruiting
NCT06764875 2026-05-12
A Phase â…¢ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
AstraZeneca
Phase 3 Recruiting
NCT06271837 2026-05-11
A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors
AstraZeneca
Phase 2 Active not recruiting
NCT07497386 2026-05-11
A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Recruiting
NCT06048718 2026-05-08
TUXEDO-4
MedSIR
Phase 2 Active not recruiting
NCT06750484 2026-05-06
Trial of Trastuzumab Deruxtecan in Previously Treated HER2
Yale University
Phase 2 Recruiting
NCT06989112 2026-05-06
DE-01
AstraZeneca
Phase 3 Recruiting
NCT05417594 2026-05-05
CERTIS1
AstraZeneca
Phase 1/2 Recruiting
NCT05408845 2026-05-04
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
NRG Oncology
Phase 2 Recruiting
NCT06172127 2026-04-29
DEMETHER
MedSIR
Phase 2 Active not recruiting
NCT07553390 2026-04-28
Phase 1b Study Of TRICK-NK In Combination With T-Dxd In Treatment-Refractory Breast Cancers
M.D. Anderson Cancer Center
Phase 1 Not yet recruiting
NCT03742102 2026-04-24
BEGONIA
AstraZeneca
Phase 1/2 Active not recruiting
NCT07543536 2026-04-22
MEGA-TACT-BC3
Sun Yat-sen University
Phase 3 Not yet recruiting
NCT05480384 2026-04-21
Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction
Brown University
Phase 2 Active not recruiting
NCT07340164 2026-04-20
TROY
Yonsei University
Phase 2 Recruiting
NCT04686305 2026-04-13
DL03
AstraZeneca
Phase 1 Recruiting
NCT04482309 2026-04-09
DPT02
AstraZeneca
Phase 2 Active not recruiting
NCT07198724 2026-04-09
ERADICATE
Dana-Farber Cancer Institute
Phase 1/2 Recruiting
NCT05034887 2026-04-08
Phase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant Treatment, or Trastuzumab Deruxtecan Plus Capecitabine Plus Durvalumab(MEDI4736) in the Preoperative and Postoperative Adjuvant Treatment for Patients With HER2 Positive Gastric and Gastroesophageal Junction Adenocarcinoma
National Cancer Center Hospital East
Phase 2 Active not recruiting
NCT05950945 2026-04-08
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
Daiichi Sankyo
Phase 3 Recruiting
NCT05048797 2026-04-03
A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations
AstraZeneca
Phase 3 Active not recruiting
NCT05744375 2026-04-02
TRANSCENDER
Spanish Breast Cancer Research Group
Phase 2 Terminated
NCT06486883 2026-04-02
PONTIAC
MedSIR
Phase 2 Recruiting
NCT07371585 2026-03-27
TOP-REAL
SOLTI Breast Cancer Research Group
Phase 2 Recruiting
NCT04539938 2026-03-23
HER2CLIMB-04
Seagen Inc.
Phase 2 Completed
NCT04639219 2026-03-23
DPT01
AstraZeneca
Phase 2 Active not recruiting
NCT07015697 2026-03-20
A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors
Daiichi Sankyo
Phase 1 Recruiting
NCT03424005 2026-03-16
Morpheus-panBC
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT06731478 2026-03-16
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
Daiichi Sankyo
Phase 3 Recruiting
NCT05845450 2026-03-12
Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)
Gruppo Oncologico del Nord-Ovest
Phase 2 Recruiting
NCT07454668 2026-03-06
Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain Metastases
Baptist Health South Florida
Phase 1 Not yet recruiting